NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NHLBI E-254-2003-3-US-21 Use of Nitrite Salts For The Treatment Of Cardiovascular Conditions US CON 14/589,324 9700578 Expired PDF
NIAID E-043-2014-2-PCT-01 NEUTRALIZING ANTIBODIES TO HIV-1 ENV AND THEIR USE PCT PCT PCT/US2015/010180 Expired
NCI E-132-2010-0-US-04 Methods Of Diagnosing And Prognosing Colonic Polyps US CON 14/589,238 Abandoned
NCI E-053-2015-0-US-01 Myc G-quadruplex Stabilizing Small Molecules And Their Use US 62/099,938 Abandoned
NIAID E-060-2015-0-US-01 NOVEL, MULTIVALENT, NANOPARTICLE-BASED VACCINES FOR INFLUENZA VIRUS US 62/098,755 Abandoned
NCATS E-244-2014-0-US-01 Small Molecule Inhibitors Of Lactate Dehydrogenase and Methods of Use Thereof US 62/097,226 Abandoned
NIAID E-260-2014-0-US-01 Structure-based Design Of A Fusion Glycoprotein Vaccine For Metapneumovirus US 62/096,744 Abandoned
NICHD E-039-2015-0-US-01 Adeno-Associated Virus Vectors Encoding Modified G6PC For The Treatment of Glycogen Storage Disease US 62/096,400 Abandoned
NCI E-146-2007-1-US-02 Selenocysteine Mediated Hybrid Antibody Molecules US CON 14/579,180 Abandoned
NCATS E-243-2014-0-US-01 Mutant IDH1 Inhibitors Useful for Treating Cancer US 62/095,322 Abandoned
NEI E-089-2011-0-DE-01 Calcineurin Inhibitor-antibody Conjugates For The Treatment Of Th17 Driven Inflammatory Diseases. DE EP 14819058.0 Issued
NEI E-089-2011-0-FR-01 Calcineurin Inhibitor-antibody Conjugates For The Treatment Of Th17 Driven Inflammatory Diseases. FR EP 14819058.0 Issued
NEI E-089-2011-0-GB-01 Calcineurin Inhibitor-antibody Conjugates For The Treatment Of Th17 Driven Inflammatory Diseases. GB EP 14819058.0 Issued
NEI E-089-2011-0-EP-03 Calcineurin Inhibitor-antibody Conjugates For The Treatment Of Th17 Driven Inflammatory Diseases. EP National Stage 14819058.0 Issued
NIA E-049-2001-0-AU-24 GLP-1 Exendin-4 Peptide Analogs and Uses Thereof AU DIV 2014277804 Expired
NCATS E-326-2008-0-US-10 Activators Of Human Pyruvate Kinase US DIV 14/576,333 9290512 Issued PDF
NCI E-549-2013-0-PCT-02 IMMUNOGENIC JC POLYOMAVIRUS COMPOSITIONS AND METHODS OF USE PCT PCT PCT/US2014/071621 Expired
NEI E-089-2011-0-PCT-02 Calcineurin Inhibitor-antibody Conjugates For The Treatment Of Th17 Driven Inflammatory Diseases. PCT PCT PCT/GB2014/053804 Expired
NINDS E-088-2012-0-US-03 METHODS AND COMPOSITIONS FOR IDENTIFYING JC VIRUS US National Stage 14/408,919 9631243 Issued PDF
NCI E-050-2014-0-CA-04 Cancer Immunotherapy by Delivering Class II MHC Antigens Using a VLP-Replicon CA National Stage 2934075 Issued
NCI E-050-2014-0-KR-12 Cancer Immunotherapy by Delivering Class II MHC Antigens Using a VLP-Replicon KR National Stage 10-2016-7019097 Issued
NCI E-050-2014-0-MX-13 Cancer Immunotherapy by Delivering Class II MHC Antigens Using a VLP-Replicon MX National Stage MX/a/2016/007726 Issued
NCI E-050-2014-0-NL-30 CANCER IMMUNOTHERAPY BY DELIVERING CLASS II MHC ANTIGENS AND A COSTIMULATORY SIGNAL PROTEIN USING A VLP-REPLICON NL EP 20150087.3 Issued
NCI E-050-2014-0-ES-25 CANCER IMMUNOTHERAPY BY DELIVERING CLASS II MHC ANTIGENS AND A COSTIMULATORY SIGNAL PROTEIN USING A VLP-REPLICON ES EP 20150087.3 Issued
NCI E-050-2014-0-BE-22 CANCER IMMUNOTHERAPY BY DELIVERING CLASS II MHC ANTIGENS AND A COSTIMULATORY SIGNAL PROTEIN USING A VLP-REPLICON BE EP 20150087.3 Issued
NCI E-050-2014-0-CH-23 CANCER IMMUNOTHERAPY BY DELIVERING CLASS II MHC ANTIGENS AND A COSTIMULATORY SIGNAL PROTEIN USING A VLP-REPLICON CH EP 20150087.3 Issued
NCI E-050-2014-0-GB-27 CANCER IMMUNOTHERAPY BY DELIVERING CLASS II MHC ANTIGENS AND A COSTIMULATORY SIGNAL PROTEIN USING A VLP-REPLICON GB EP 20150087.3 Issued
NCI E-050-2014-0-FR-26 CANCER IMMUNOTHERAPY BY DELIVERING CLASS II MHC ANTIGENS AND A COSTIMULATORY SIGNAL PROTEIN USING A VLP-REPLICON FR EP 20150087.3 Issued
NCI E-050-2014-0-DE-24 CANCER IMMUNOTHERAPY BY DELIVERING CLASS II MHC ANTIGENS AND A COSTIMULATORY SIGNAL PROTEIN USING A VLP-REPLICON DE EP 20150087.3 Issued
NCI E-050-2014-0-IT-29 CANCER IMMUNOTHERAPY BY DELIVERING CLASS II MHC ANTIGENS AND A COSTIMULATORY SIGNAL PROTEIN USING A VLP-REPLICON IT EP 20150087.3 Issued
NCI E-050-2014-0-IE-28 CANCER IMMUNOTHERAPY BY DELIVERING CLASS II MHC ANTIGENS AND A COSTIMULATORY SIGNAL PROTEIN USING A VLP-REPLICON IE EP 20150087.3 Issued
NCI E-050-2014-0-IN-11 Cancer Immunotherapy by Delivering Class II MHC Antigens Using a VLP-Replicon IN National Stage 201617023312 Issued
NCI E-050-2014-0-JP-06 Cancer Immunotherapy by Delivering Class II MHC Antigens Using a VLP-Replicon JP National Stage 2016-558546 Issued
NCI E-050-2014-0-AU-03 Cancer Immunotherapy by Delivering Class II MHC Antigens Using a VLP-Replicon AU National Stage 2014365777 Issued
NCI E-050-2014-0-SG-14 Cancer Immunotherapy by Delivering Class II MHC Antigens Using a VLP-Replicon SG National Stage 11201604868Y Issued
NCI E-203-2004-0-US-03 Improved Replication-Competent Adenoviral Vectors US DIV 14/571,942 9216214 Issued PDF
NCI E-050-2014-0-PCT-02 Cancer Immunotherapy by Delivering Class II MHC Antigens Using a VLP-Replicon PCT PCT PCT/US2014/070552 Expired
NCI E-050-2014-0-CN-09 Cancer Immunotherapy by Delivering Class II MHC Antigens Using a VLP-Replicon CN National Stage 201480074163.2 Pending
NCI E-050-2014-0-BR-08 Cancer Immunotherapy by Delivering Class II MHC Antigens Using a VLP-Replicon BR National Stage BR112016013804-0 Abandoned
NCI E-050-2014-0-EP-05 Cancer Immunotherapy by Delivering Class II MHC Antigens Using a VLP-Replicon EP National Stage 14824680.4 Abandoned
NIAID E-048-2015-0-US-01 Detection And Discrimination Of Classical And Atypical L-Type BSE Strains By RT-QuIC US 62/092,645 Abandoned
NCI E-108-2004-2-US-02 Methods for Identifying, Diagnosing, and Predicting Survival of Lymphomas US CON 14/570,316 1037-07-15 Issued PDF
NIA E-045-2012-0-US-02 THIO COMPOUNDS US DIV 14/571,138 9084783 Issued PDF
NCI E-047-2014-0-CA-03 Multi-Epitope TARP Peptide Vaccine And Uses Thereof CA National Stage 2932248 Issued
NICHD E-348-2013-0-US-05 Biomarker Test for Prediction or Early Detection of Preeclampsia and/or HELLP Syndrome US National Stage 14/407,516 1067-06-10 Issued PDF
NCI E-047-2014-0-AU-07 Multi-Epitope TARP Peptide Vaccine And Uses Thereof AU National Stage 2014361788 Issued
NCI E-047-2014-0-DK-12 Multi-Epitope TARP Peptide Vaccine And Uses Thereof DK EP 14831120.2 Issued
NCI E-047-2014-0-EP-04 Multi-Epitope TARP Peptide Vaccine And Uses Thereof EP National Stage 14831120.2 Issued
NCI E-047-2014-0-NL-13 Multi-Epitope TARP Peptide Vaccine And Uses Thereof NL EP 14831120.2 Issued
NCI E-047-2014-0-DE-08 Multi-Epitope TARP Peptide Vaccine And Uses Thereof DE EP 14831120.2 Issued